PleoPharma has secured US Food and Drug Administration (FDA) Fast Track designation for PP-01, its lead asset for the mitigation of cannabis withdrawal syndrome in patients with cannabis use disorder. “We are pleased that PP-01 has been granted Fast Track designation and are grateful to the FDA… Read More
Brain disease specialist Aelis Farma has announced results from the clinical Phase IIB trial study of AEF0117, evaluating its efficacy and safety in treatment-seeking participants with moderate to severe Cannabis Use Disorder (CUD) that used cannabis ≥5 days/week at baseline. In this study population, 82% of… Read More
New research has linked semaglutide (the active ingredient in Wegovy and Ozempic) with improved smoking cessation. Rong Xu and colleagues at the Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, US, have reported a reduced desire to smoke in patients… Read More
A US study suggests Novo Nordisk’s GLP-1 receptor agonist Ozempic (semaglutide), which is approved as a treatment for diabetes and weight loss (as Wegovy), could reduce the risk of cancer. Ozempic has been in the spotlight recently following study data proving that patients taking it had… Read More
Dr Currien MacDonald, Medical Chair Director at WCG, discusses the challenges and opportunities presented by cannabis research. The recent interest in cannabinoids as potential sources for medicinal use has been a long time coming. Advances in brain science and modern chemistry are supporting a new generation of investigation into cannabinoids,… Read More
DDW Editor Reece Armstrong speaks to Tracy M Woody, President and Chief Executive Officer of Cessation Therapeutics, about the company’s goal to develop an antibody therapy to prevent fentanyl overdoses. Cessation Therapeutics is a pharmaceutical company that is developing antibody therapies to prevent and reverse overdosing… Read More
